Citations 1
4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2 -encephalopathy
Hedrich, Ulrike B. S. , Lauxmann, Stephan , Wolff, Markus , Synofzik, Matthis , Bast, Thomas , Binelli, Adrian , Martínez-Ulloa, Pedro, Allen, Nicholas M. , King, Mary D. , Gorman, Kathleen M. , Zeev, Bruria Ben , Tzadok, Michal , Marjanović, Dragan , Lutz, Florian , Ashraf, Harshad Pannikkaveettil , Torge, Kirsten, Yan, Pu , Boßelmann, Christian M. , Schwarz, Niklas , Fudali, Monika , Serratosa, José M , Gorman, Kathleen M , Zeev, Bruria Ben , Wong-Kisiel, Lily C. , Marjanovic, Dragan , Rubboli, Guido , Lutz, Florian , Ashraf, Harshad Pannikkaveettil , Bosselmann, Christian , Schwarz, Niklas , Fudali, Monika , Lerche, Holger , Synofzik, Matthis , Serratosa, José M. , Martínez-Ulloa, Pedro, Wong‐Kisiel, Lily C. , Rubboli, Guido , Sisodiya, Sanjay , Yan, Pu
Science Translational Medicine | September 2, 2021 | Volume: 13 | Issue: 609 | Pages: No page available
4-Aminopyridine is a potential therapeutic option for a subgroup of patients with KCNA2 -encephalopathy and gain-of-function variants.